PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Both companies show declining cash positions (-7.89% vs AXSM's -12.08%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Cash + STI yoy 0.5-0.75x AXSM's -12.08%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
0.5-0.75x AXSM's -11.43%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-4.83%
Below half AXSM's 34.13%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Below half of AXSM's 10.40%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
0.5-0.75x AXSM's -11.39%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-25.56%
Less than half of AXSM's 65.81%. David Dodd sees a more disciplined AP approach or lower volume.
-49.71%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
-18.75%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-24.27%
Less than half of AXSM's 30.40%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Less than half of AXSM's 30.40%. David Dodd sees far fewer liability expansions relative to competitor.
5.27%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
-5.68%
Below half AXSM's -34.33%. Michael Burry suspects major net losses or high dividends vs. competitor.
-17.53%
Less than half of AXSM's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half AXSM's -15.35%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
0.5-0.75x AXSM's -11.39%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Higher Total Debt Growth compared to AXSM's zero value, indicating worse performance.
7.55%
50-75% of AXSM's 12.08%. Bruce Berkowitz notes comparatively lower net debt expansion.